Orchid Pharma Ltd: Stock Analysis & Fundamentals

Updated this week

Orchid Pharma Ltd (Pharma - API) — fundamental analysis, earnings data, and key metrics. PE: 98.1. ROE: 8.2%. This stock is not currently in the Nifty 500 momentum outperformers list.

What's Happening

💪Debt reduced 91% YoY — balance sheet strengthening

Key Numbers

Current Price

₹502

Market Cap

2.5K Cr

Valuation

N/A

Other Top Pharma - API Stocks Beating Nifty 500

Senores Pharmaceuticals Ltd

Average

+8.4%

Ind-Swift Laboratories Ltd

← Back to Pharma - API Dashboard

Frequently Asked Questions: Orchid Pharma Ltd

Based on publicly available financial data. This is educational research, not investment advice.

What were Orchid Pharma Ltd's latest quarterly results?

Orchid Pharma Ltd's latest quarterly results (Dec 2025) show

PAT Growth YoY: -161.9%
Revenue Growth YoY: -4.6%
Operating Margin: 1.0%

What is Orchid Pharma Ltd's current PE ratio?

Orchid Pharma Ltd's current PE ratio is 98.1x.

Current PE: 98.1x
Market Cap: 2.5K Cr

What is Orchid Pharma Ltd's price-to-book ratio?

Orchid Pharma Ltd's price-to-book ratio is 2.0x.

Price-to-Book (P/B): 2.0x
Book Value per Share: ₹251
Current Price: ₹502

Is Orchid Pharma Ltd a fundamentally strong company?

Orchid Pharma Ltd's fundamental strength based on key financial ratios

Return on Capital (ROCE): 8.0%

Is Orchid Pharma Ltd debt free?

Orchid Pharma Ltd has a debt-to-equity ratio of N/A.

Total Debt: ₹282 Cr

What is Orchid Pharma Ltd's return on equity (ROE) and ROCE?

Orchid Pharma Ltd's return ratios over recent years

FY2023: ROCE 5.0%
FY2024: ROCE 9.0%
FY2025: ROCE 8.0%

Is Orchid Pharma Ltd's cash flow positive?

Orchid Pharma Ltd's operating cash flow is positive (FY2025).

Cash from Operations (CFO): ₹19 Cr
Free Cash Flow (FCF): ₹-8 Cr
CFO/PAT Ratio: 19% (weak cash conversion)

What is Orchid Pharma Ltd's dividend yield?

Orchid Pharma Ltd currently does not pay a significant dividend (yield 0.00%).

Dividend Yield: 0.00%
Current Price: ₹502

Who holds Orchid Pharma Ltd shares — promoters, FII, DII?

Orchid Pharma Ltd's shareholding pattern (Dec 2025)

Promoters: 69.8%
FII (Foreign): 1.2%
DII (Domestic): 19.4%
Public: 9.6%

Is promoter holding increasing or decreasing in Orchid Pharma Ltd?

Orchid Pharma Ltd's promoter holding has remained stable recently.

Current Promoter Holding: 69.8% (Dec 2025)
Previous Quarter: 69.8% (Sep 2025)
Change: 0.00% (stable)

Is Orchid Pharma Ltd a new momentum entry or an established outperformer?

Orchid Pharma Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.

Is Orchid Pharma Ltd worth studying for long term investment?

Based on quantitative research signals, here is why Orchid Pharma Ltd may be worth studying

Cash flow is positive — CFO ₹19 Cr

What is the investment thesis for Orchid Pharma Ltd?

Orchid Pharma Ltd investment thesis summary:

What is the future outlook for Orchid Pharma Ltd?

Orchid Pharma Ltd's forward outlook based on current data signals

Insufficient data for a forward assessment — monitoring for more signals

The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.